{"created":"2024-05-23T02:30:47.492564+00:00","id":2002685,"links":{},"metadata":{"_buckets":{"deposit":"8c936e9c-0398-4c9d-b972-f3a654dd9b04"},"_deposit":{"created_by":7,"id":"2002685","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2002685"},"status":"published"},"_oai":{"id":"oai:jair.repo.nii.ac.jp:02002685","sets":["1616224532673:1708403533383:1709527609563:1709529608300"]},"author_link":[],"item_10006_alternative_title_1":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_alternative_title":"(進行胃癌の3次治療における薬剤 (ニボルマブかイリノテカン)を選択する臨床因子および分子学的因子)","subitem_alternative_title_language":"ja"}]},"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2021-03-20"}]},"item_10006_degree_grantor_9":{"attribute_name":"item_10006_degree_grantor_9","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"順天堂大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"32620","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_10":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"2020年度","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10006_dissertation_number_12":{"attribute_name":"dissertation_number","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第2416号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1177/1758835920942377","subitem_relation_type_select":"DOI"}}]},"item_10006_version_type_18":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"石井, 貴大","creatorNameLang":"ja"},{"creatorName":"イシイ, タカヒロ","creatorNameLang":"ja-Kana"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2416-sinyou.pdf","filesize":[{"value":"209.2 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"審査結果の要旨","objectType":"other","url":"https://jair.repo.nii.ac.jp/record/2002685/files/MDK2416-sinyou.pdf"},"version_id":"25f45b34-3960-46cd-88f8-9efb8e98819a"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2416-ronyou.pdf","filesize":[{"value":"129.6 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"論文内容の要旨","objectType":"abstract","url":"https://jair.repo.nii.ac.jp/record/2002685/files/MDK2416-ronyou.pdf"},"version_id":"da1d8361-cf58-4b9c-af44-45d1851215a2"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2416-zenbunpu.pdf","filesize":[{"value":"841.1 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"全文【出版社版】","objectType":"fulltext","url":"https://jair.repo.nii.ac.jp/record/2002685/files/MDK2416-zenbunpu.pdf"},"version_id":"bed9832f-9566-40cd-9e5f-573d40611478"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1709529608300"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-03-20"},"publish_date":"2021-03-20","publish_status":"0","recid":"2002685","relation_version_is_last":true,"title":["Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2024-11-27T00:56:03.787401+00:00"}